Martin Shkreli

Treat IonQ (IONQ) and Rigetti (RGTI) as highly speculative: commercial uses remain uncertain, and sharp rallies can make short positions dangerous. Avoid leveraged Bitcoin (BTC) futures unless you fully understand margin and liquidation rules; the discussion offers no reliable short-term directional edge. Watch Viking Therapeutics (VKTX) for financing and clinical updates before taking a position, given concerns about cash needs and an uncertain drug-program outlook. Be cautious with semiconductor shorts such as Micron (MU) and SanDisk (SNDK): possible supply and demand headwinds were raised, but no specific targets or confirmed catalysts were provided.

• Nidec (NIDEC) is the clearest favorable new-name idea: research its motor and disk-drive exposure, with the discussion citing roughly 11× EBITDA; no price target was given.
• Lam Research (LRCX) was suggested as a possible long against SanDisk (SNDK), but the rationale was limited and the pair trade remains unconfirmed; investigate further before acting.
• AI-related NVMe flash demand may support SanDisk, but competition and sharp volatility make it a high-risk, uncertain trade rather than a clear buy.
• Avoid treating Jaguar Health (JAGX) as an investment: the discussion described a volatile, hard-to-borrow short-squeeze setup with potential for abrupt reversals.

Consider buying Ultragenyx Pharmaceutical (RARE) as an undervalued growth play with potential acquisition upside targeting $30 to $40. Buy Bloom Energy (BE) to benefit from rising AI power infrastructure demand, and accumulate Micron Technology (MU) for long-term semiconductor upside toward $1,050 to $1,500. Treat recent price dips in Meta Platforms (META) as high-conviction buying opportunities supported by robust underlying fundamentals. Short IonQ (IONQ) around $39 due to unproven commercial viability in quantum computing, along with Pfizer (PFE) amid severe drug pipeline headwinds. Lock in profits on recent price surges in Advanced Micro Devices (AMD), while strictly avoiding toxic microcaps like QCLS that face severe dilution risks.

Consider a long position in Ultragenyx Pharmaceutical (RARE) following its steep 47% sell-off, targeting a rebound toward $40–$50 per share based on its depressed valuation of roughly 2x sales. Position for upside in memory semiconductor producers like fundamentally strong Micron Technology (MU) and SanDisk, which are primed to benefit from potential U.S. tariffs on competitor SK Hynix. Consider short positions on Moderna (MRNA) as the company faces sustained downside pressure and an uncertain commercial pipeline. Watch for tactical short-selling setups in Robinhood Markets (HOOD) to capitalize on potential pullbacks following its rapid, crypto-fueled rally. Finally, stay invested in resilient enterprise software leaders like Snowflake (SNOW) as fears over AI disruption subside, while actively avoiding speculative quantum computing stocks that lack near-term commercial viability.

Rotate exposure from NVIDIA (NVDA) into Taiwan Semiconductor Manufacturing Company (TSM) to capitalize on the tech sector's structural shift toward custom ASICs. Within mega-cap tech, prioritize the stability and strong execution of Microsoft (MSFT) and Apple (AAPL) over margin-pressured peers like Amazon (AMZN) and Meta Platforms (META). Capitalize on recent clinical selloffs by buying undervalued core assets in Ultragenyx Pharmaceutical (RARE), while treating Spruce Biosciences (SPRB) as a patient, long-term opportunity toward a $500 price target. Short or avoid Capricor Therapeutics (CAPR) and Amylyx Pharmaceuticals (AMLX) ahead of expected product-launch headwinds and questionable trial data. Protect overall capital by applying disciplined Kelly Criterion position sizing and dollar-neutral sector hedging instead of taking oversized, unhedged bets.

Consider a long position in Spruce Biosciences (SPRB) for upside on anticipated FDA approval, while risk-tolerant investors can target an oversold rebound in Alumis Inc. (ALMS).

Actively position for downside or hold short exposure on Moderna (MRNA) and Kinsale Capital Group (KNSL) due to deteriorating growth trajectories and unfavorable valuations.

Avoid or immediately exit long positions in Inventiva (IVA) ahead of upcoming binary PPAR clinical trial readouts that carry severe downside risk toward zero.

Steer clear of speculative traps, including the heavily dilutive GoPro (GPRO) reverse merger, the overvalued AI neo-cloud provider Nebius Group (NBIS), and highly manipulated micro-cap meme coins.

Protect capital during market uncertainty by allocating funds toward cash and fixed-income bonds yielding roughly 5% to preserve purchasing power against inflation.

For NVIDIA (NVDA), look to fade sharp post-earnings spikes while holding for long-term growth, as projected 70% revenue expansion in fiscal 2028 outweighs near-term gross margin pressure.

Sell or short Salesforce (CRM) around the $231 post-earnings level, where the recent double-digit rally appears driven by short-covering rather than strong underlying growth.

Maintain a high-conviction short position on Moderna (MRNA) to profit from ongoing cash burn and declining core franchise revenues.

Deploy conservatively sized short trades on Capricor Therapeutics (CAPR) due to high skepticism surrounding lead asset FDA approval, while strictly managing risk against potential short squeezes.

Look for tactical intraday short setups on Meta Platforms (META) during market pullbacks as the stock absorbs headwinds from a potential $16 billion regulatory settlement.

Investors can capitalize on downside momentum by shorting Moderna (MRNA) toward a target of $100, while also targeting high-conviction short positions in Capricor Therapeutics (CAPR) down to $6.00 and SELLAS Life Sciences (SLS) due to high clinical trial failure risks.

For bullish healthcare plays, Spruce Biosciences (SPRB) offers strong upside potential following recent positive news catalysts, and Biohaven (BHVN) represents a high-conviction long-term hold driven by proven management execution.

In the semiconductor space, consider a long position in Broadcom (AVGO) to benefit from the growing enterprise shift toward custom artificial intelligence chip design.

Active traders should look to short or avoid speculative rallies in the Quantum Computing Sector, as recent price surges lack fundamental revenue backing.

Finally, steer clear of microcap Solana Meme Tokens, which carry severe risks of capital loss due to illiquid markets and high price manipulation.

Buy oversold dips in Applied Optoelectronics (AAOI) following its recent capital raise, targeting a mean-reversion rebound toward the $115 to $118 range.

Establish a high-conviction speculative long position in Spruce Biosciences (SPRB), which offers 5x to 10x upside toward a $500 target as the market catches up to its rare disease drug pipeline.

Accumulate long-term exposure to the silicon photonics and optical components theme via data center suppliers Lumentum (LITE), Credo (CRDO), Fabrinet (FN), and Coherent (COHR) to ride AI infrastructure expansion.

Avoid long positions in Moderna (MRNA) and instead use temporary price rallies as short-selling opportunities given ongoing declines in vaccine demand.

Consider a tactical short-term dip buy on SanDisk around the $1,450–$1,460 level to capture an oversold bounce, keeping strict stop-losses in place to protect against broader semiconductor downturns.

• Consider shorting Moderna (MRNA) on upward price spikes, targeting a pullback into the $140 to $130 range as short-term buying momentum fades.
• In the semiconductor sector, initiate a pair trade by buying Intel (INTC) near the $90–$93 support level while shorting Broadcom (AVGO) as a relative valuation hedge.
• Take a contrarian long position in AppLovin (APP) to capture upside from its rapid revenue and earnings growth despite elevated short interest.
• Look to short Sellas Life Sciences (SLS) ahead of its binary clinical trial results over the next 4 to 6 weeks, while setting tight risk limits against potential short squeezes up to $20.
• Hedge existing technology portfolios against macroeconomic volatility by selectively shorting high-valuation software names like Palantir (PLTR), Datadog (DDOG), or Salesforce (CRM) once upward momentum stalls.

Traders can look to short Moderna (MRNA) following its overextended short-squeeze spike above $160, or alternatively buy Merck (MRK) as a lower-volatility way to gain exposure to their joint cancer vaccine breakthrough. Sellas Life Sciences (SLS) presents a high-conviction short opportunity ahead of its unpromising clinical trial readout expected between December and January, which carries severe downside risk toward zero. Investors should accumulate quality Enterprise Software leaders like ServiceNow (NOW) and Salesforce (CRM) as overblown fears of generative AI disruption begin to fade and clear the path for a recovery. For Nebius Group (NBIS), wait for the temporary arbitrage selling pressure from its convertible debt offering to settle before stepping in to buy the dip. In the semiconductor sector, favor Marvell Technology (MRVL) following its major custom silicon win with Google, while exercising caution on Broadcom (AVGO) due to customer diversification risks.

Consider buying shares of OmniAb (OABI) to capture significant long-term royalty upside tied to its high-potential drug candidate partnership with Johnson & Johnson. Take advantage of recent pullbacks in cloud infrastructure by dip-buying Microsoft (MSFT) and Oracle (ORCL) for an attractive rebound opportunity. Position for downside in SELLAS Life Sciences Group (SLS) ahead of its upcoming 80th clinical milestone readout, where expert sentiment indicates a low 25% probability of trial success. Target Cerebras Systems for a short-term mean-reversion trade to capitalize on an overextended 14% to 18% price surge that lacked a fundamental catalyst. Prepare to short SanDisk on signs of technical exhaustion, as the broader memory cycle appears near its peak and risks future supply saturation.

Capitalize on the artificial intelligence infrastructure boom by holding market leader NVIDIA (NVDA) as an essential long-term investment for your portfolio. Buy CoreWeave (CRWV) to capture explosive growth driven by massive enterprise demand, a $104 billion revenue backlog, and raised 2026 revenue guidance up to $13.2 billion. Accumulate shares of Lumentum Holdings (LITE) to benefit from robust optical networking demand, supported by strong gross margins and forward guidance of $1.225 billion. Trade SanDisk (SNDK) cautiously on a short-term basis while avoiding long-term positions due to looming structural price pressures from Chinese competitors. Approach Super Micro Computer (SMCI) with strict risk management as choppy trading persists following mixed quarterly results.

Consider buying Intel (INTC) as a potential long-term opportunity if you are comfortable with dilution risks tied to its massive infrastructure buildout. Anticipate and manage through historical volatility in NVIDIA (NVDA), utilizing its newly formed AI compute financing partnerships as a fundamental growth catalyst. Approach Palantir Technologies (PLTR) with extreme caution and look for short-term mean-reversion trades to fade overextended upward momentum. Aggressive short-term traders can target SanDisk (SNDI) on the short side with a price target between $1,100 and $1,300, banking on margin pressure from emerging Chinese competitors. Exercise strict risk management when shorting binary-outcome biotech plays like Silence Therapeutics (SLNS) or Apellis Pharmaceuticals (APRE) to avoid violent short squeezes from unexpected positive trial readouts.

Capitalize on natural price volatility by establishing a long position in Intel (INTC) to capture strong quarterly momentum and upward swings. Neutralize broader market risk by pairing your Intel holding with a tactical short position in Nvidia (NVDA) to hedge against semiconductor sector pullbacks. Exercise caution and strictly manage position sizes to avoid over-leveraging during volatile market sessions driven by macroeconomic news. Avoid speculative exposure to SanDisk, as it carries extreme downside beta and will suffer severe drawdowns if an artificial intelligence correction occurs.